Engage & Connect: A Psychotherapy for Postpartum Depression

Description

This randomized controlled trial compares a novel psychotherapy, Engage \& Connect, with a Symptom Review and Psychoeducation intervention, tailored to reduce postpartum depression. The study includes 9-weeks interventions, delivered remotely. It will examine changes in social isolation, processing of social rewards and depression severity over 9 weeks of treatment.

Conditions

Postpartum Depression

Talk to us

Study Overview

On this page

Study Details

Study overview

This randomized controlled trial compares a novel psychotherapy, Engage \& Connect, with a Symptom Review and Psychoeducation intervention, tailored to reduce postpartum depression. The study includes 9-weeks interventions, delivered remotely. It will examine changes in social isolation, processing of social rewards and depression severity over 9 weeks of treatment.

Engage & Connect: A Novel Social Reward Psychotherapy for Postpartum Depression

Engage & Connect: A Psychotherapy for Postpartum Depression

Condition
Postpartum Depression
Intervention / Treatment

-

Contacts and Locations

New York

Weill Cornell Medicine, New York, New York, United States, 10022

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Up to 1 year post-delivery
  • 2. Edinburgh Postnatal Depression Scale (EPDS) score ≥ 10.
  • 3. Off antidepressants or on a stable dose of an antidepressant for 8 weeks and do not intend to change the dose in the next 10 weeks.
  • 4. Capacity to provide consent for research assessment and treatment.
  • 5. Speaks English proficiently
  • 1. Intent or plan to attempt suicide in the near future
  • 2. Ongoing psychotherapy (no more than once every 8 weeks or during the duration of the intervention)
  • 3. Active substance abuse or dependence
  • 4. Severe fetal anomalies, stillbirth or infant death at time of enrollment for index pregnancy
  • 5. History or presence of psychiatric diagnoses other than major depressive disorder without psychotic features, generalized anxiety disorder, persistent depressive disorder, or specific phobia.
  • 6. Use of psychotropic drugs or cholinesterase inhibitors other than use of ≤ 0.5 mg of lorazepam daily up to seven times per week.

Ages Eligible for Study

to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Weill Medical College of Cornell University,

Nili Solomonov, PhD, PRINCIPAL_INVESTIGATOR, Weill Medical College of Cornell University

Study Record Dates

2025-07